A phase 1 study of NCT-10004 in healthy volunteers
Latest Information Update: 09 Feb 2022
At a glance
- Drugs NCT 10004 (Primary)
- Indications Atopic dermatitis; Pruritus
- Focus Adverse reactions
- 01 Oct 2019 According to a NeuroCycle Therapeutics media release, company expects to initiate this study in 2020.
- 19 Feb 2019 New trial record
- 13 Feb 2019 According to a NeuroCycle Therapeutics media release, the company expects to initiate this study by the end of 2019.